Semapimod (CNI 1493.

Semapimod (CNI 1493.

Selurampanel (BGG 492) is a selective, orally active and competitive AMPA receptor (AMPAR) antagonist with IC50 of 0.19 uM.

Selgantolimod is a novel toll-​like receptor TLR8 modulator for the treatment of HIV infection..

SEL24-B489 (SEL24) is a potent, dual PIM and FLT3-ITD inhibitor with Kd of 2/2/3 nM for PIM1/2/3, Kd of 160/16 nM for FLT3-WT/FLT3-ITD, respectively.

SEL24-B489 (SEL24) is a potent, dual PIM and FLT3-ITD inhibitor with Kd of 2/2/3 nM for PIM1/2/3, Kd of 160/16 nM for FLT3-WT/FLT3-ITD, respectively.

SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.

SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.

Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR..

Secnidazole (Flagentyl)

SecinH3 is a selective cytohesin inhibitor with IC50 of 2.4 μM, 5.4 μM, 5.4 μM, 5.6 μM, 5.6 μM, and 65 μM for hCyh2, hCyh1, mCyh3, hCyh3, drosophila steppke, and yGea2-S7, respectively.

SDZ 220-581 is a potent, competitive NMDA receptor antagonist with pKi of 7.7, fully protects against maximal electroshock seizures (MES) at oral doses of 10 mg/kg in rats and in mice. .

SD-1029 (NSC 371488) is a potent inhibitor of Stat3 activation, suppresses EGFP-Stat3 nuclear translocation at 10 uM in both BHK-21 and U2-OS cells.

Scytonemin is a marine natural product that inhibits PLK1 with IC50 of 2 uM against recombinant enzyme, shows similar potentcy for Myt1, Chk1,Cdk1/cyclin B and PKCβ2, less potent against PKA and Tie2.

Sclerotigenin is a natural diazepine originally isolated from P. sclerotigenum that acts as an insect growth regulator.1 It reduces the growth rate of first instar H. zea larvae by 42% relative to controls when administered in the standard test diet at 20

SCH 900229 is a potent and presenilin 1 selective, and orally active inhibitor of γ-secretase (Aβ40 IC50=1.3 nM).

SCH 412348 is a potent and highly selective A2A receptor competitive antagonist with Ki of 0.6 nM.

SC-68448 (SC68448) is a potent, selective peptidomimetic antagonist of the integrin αvβ3 with IC50 of 1 nM, 100-fold selectivity over αIIbβ3.

S-C025 is a highly potent antagonist of oxoeicosanoid receptor (OXE receptor) with IC50 of 0.12 nM.

S-C025 is a highly potent antagonist of oxoeicosanoid receptor (OXE receptor) with IC50 of 0.12 nM, inhibits 5-oxo-ETE-induced calcium mobilization in human neutrophils..

SBE-β-CD (Sulfobutylether-β-Cyclodextrin; Captisol) is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs; Captisol is the trademark of SBE-β-CD registered by Ligand Pharmaceuticals.

SB772077B (SB-772077B, SB77, SB-772077-B) is a potent, selective Rho kinase (ROCK) inhibitor with IC50 of 5.6 nM and 6.0 nM for ROCK1 and ROCK2, respectively.

SB-699393 is a potent, selective and CNS penetrant B-Raf inhibitor with Kd of 7.2 nM.

SB-435495 is a potent, orally active inhibitor of Lp-PLA2 with IC50 of 0.06 nM.

SB-399885 is a potent, selective, brain penetrant 5-HT6 receptor antagonist with pKi of 9.11 and 9.02 for human recombinant and native 5-HT6 receptors.

SB273005 is a potent integrin inhibitor with Ki of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.

SB269652 is a potent, selective, negative allosteric modulator of dopamine D2 and D3 receptors, abolishes specific binding of [3H]nemanopride and [3H]spiperone to CHO-transfected D3 receptors with IC50 of1.86 and 0.18 nM.

SB-258585 is a potent, selective and orally active 5-HT6 receptor antagonist with Ki of 8.9 nM, >160-fold selectivity over other 5-HT receptor subtypes.

SB 737050A is a potent, selective 5-HT6 receptor antagonist to prevent relapse intio addiction..

SB 206553 is a potent and selective 5-HT2B/5-HT2C receptor antagonist with pA2 of 8.89 for rat 5-HT2B, pKi of 7.92 for human 5-HT2C, displays >80-fold selectivity over other 5-HT receptor subtypes.